Compare · TLIS vs TXG
TLIS vs TXG
Side-by-side comparison of Talis Biomedical Corporation (TLIS) and 10x Genomics Inc. (TXG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both TLIS and TXG operate in Biotechnology: Laboratory Analytical Instruments (Health Care), so they compete in similar markets.
- TXG carries a market cap of $7.65B.
- TXG has hit the wire 10 times in the past 4 weeks while TLIS has been quiet.
- TXG has more recent analyst coverage (25 ratings vs 5 for TLIS).
- Company
- Talis Biomedical Corporation
- 10x Genomics Inc.
- Price
- -
- -
- Market cap
- -
- $7.65B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2019
- News (4w)
- 0
- 10
- Recent ratings
- 5
- 25
Talis Biomedical Corporation
Talis Biomedical Corporation operates as a molecular diagnostic company. It is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. The company is also developing Talis One assay kits for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A and influenza B plus SARS-CoV-2. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.
10x Genomics Inc.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Latest TLIS
- Amendment: SEC Form SC 13D/A filed by Talis Biomedical Corporation
- SEC Form 15-12G filed by Talis Biomedical Corporation
- SEC Form 25-NSE filed by Talis Biomedical Corporation
- Talis Biomedical Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form S-8 POS filed by Talis Biomedical Corporation
- SEC Form S-8 POS filed by Talis Biomedical Corporation
- SEC Form S-8 POS filed by Talis Biomedical Corporation
- SEC Form S-8 POS filed by Talis Biomedical Corporation
- Large owner Leonard Braden Michael bought $44,240 worth of shares (30,100 units at $1.47) (SEC Form 4)
- Talis Biomedical Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Latest TXG
- Amendment: SEC Form SCHEDULE 13G/A filed by 10x Genomics Inc.
- Chief Executive Officer Saxonov Serge sold $1,949,900 worth of shares (31,000 units at $62.90), decreasing direct ownership by 3% to 1,019,249 units (SEC Form 4)
- Shanghai Precision Diagnostics and Fudan University Shanghai Cancer Center Launch Breast Cancer Biomarker Study Using 10x Genomics' Xenium Platform
- SEC Form 3 filed by new insider Satpathy Ansuman
- New insider Gilliam Joseph E claimed ownership of 31 shares (SEC Form 3)
- 10x Genomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- 10x Genomics Reports Third Quarter 2026 Financial Results
- 10x Genomics Inc. filed SEC Form 8-K: Leadership Update
- 10x Genomics Launches Sentira Single Cell, A New Agentic AI Experience for Chromium Analysis
- 10x Genomics to Participate in the 2026 Jefferies Global Healthcare Conference